Answers are grounded in this paper and cite their sources.
Continuous positive airway pressure (CPAP) has been diffusely applied outside the Intensive Care Unit in patients with acute hypoxemic respiratory failure (AHRF) due to Coronavirus-19 disease. A PubMed query was performed using the following key words: “COVID-19,” “continuous positive airway pressure,” “respiratory failure,” “pneumonia.” Most recent papers written in English were selected. Studies discussing pathophysiologic issues were prioritized. Reports of single cases were excluded. The content of the selected papers was summarized as a brief narrative review. The use of CPAP in COVID-19 related AHRF is based on the assumption that it may lead to increased resistance in the small vessels of non-dependent regions of the lung, favoring the redistribution of perfusion to newly recruited depending areas when the hypoxic vasoconstriction mechanism is lost. CPAP might reduce the respiratory work and distress and avoid the reduction of the residual functional capacity, improving the compliance of the thoracic-pulmonary system and increasing the percentage of ventilated alveoli. Finally, CPAP might improve the oxygenation even in refractory hypoxemia during conventional oxygen therapy with moderately preserved pulmonary compliance. Always being alert to consider tracheal intubation in patients with clinical signs of unresponsive acute respiratory failure, we suggest the use of CPAP in COVID-19 related AHRF in the first phases of the clinical course, for hemodynamically stable patients, with preserved neurological status, intact respiratory dynamics, elevate respiratory rate and mild-severe desaturation.
No takes yet. Share an insight, caveat, or question.
Piazza et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: